GHIT Fund and Medicines Patent Pool strengthen collaboration

30 October 2023

The Global Health Innovative Technology (GHIT) Fund and United Nations-backed Medicines Patent have signed a Memorandum of Understanding (MOU) to strengthen their collaboration to improve access to medicines.

The Japan-based GHIT Fund is a public-private partnership that was formed between the government of Japan, multiple pharmaceutical companies, the Bill & Melinda Gates Foundation, Wellcome, and the United Nations Development Program.

It has invested in the research and development of drugs, vaccines and diagnostics to manage and address infectious diseases such as tuberculosis, malaria and neglected tropical diseases (NTDs), which are highly prevalent in low- and middle-income countries (LMICs).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK